Parenterally Administered Norovirus GII.4 Virus-Like Particle Vaccine Formulated with Aluminum Hydroxide or Monophosphoryl Lipid A Adjuvants Induces Systemic but Not Mucosal Immune Responses in Mice
Norovirus (NoV) is a main cause of acute gastroenteritis across all ages worldwide. NoV vaccine candidates currently in clinical trials are based on noninfectious highly immunogenic virus-like particles (VLPs) delivered intramuscularly (IM). Since NoV is an enteric pathogen, it is likely that mucosa...
Saved in:
Main Authors: | Suvi Heinimäki, Maria Malm, Timo Vesikari, Vesna Blazevic |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2018/3487095 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo
by: Kirsi Tamminen, et al.
Published: (2020-01-01) -
Outbreak of Norovirus GII.P17-GII.17 in the Canadian Province of Nova Scotia
by: Jason J. LeBlanc, et al.
Published: (2016-01-01) -
Emerging Norovirus GII.12 infection in 2010 in Northern Taiwan
by: Chi-Neu Tsai, et al.
Published: (2025-02-01) -
Characterization of the complete genome sequence of the recombinant norovirus GII.P16/GII.4_Sydney_2012 revealed in Russia
by: E. V. Zhirakovskaia, et al.
Published: (2020-03-01) -
Persistence of the Immune Response to an Intramuscular Bivalent (GI.1/GII.4) Norovirus Vaccine in Adults
by: Geert Leroux-Roels, et al.
Published: (2025-01-01)